Impact of Immune Checkpoint Inhibitors on Atherosclerosis Progression in Patients with Lung Cancer. (21/11/2023)
Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
